Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been waiting. It's about time!
BioVie Inc. Announces Nasdaq Listing and Pricing of $15.7 Million Public Offering
https://www.otcmarkets.com/stock/BIVI/news/BioVie-Inc-Announces-Nasdaq-Listing-and-Pricing-of-157-Million-Public-Offering?id=274402
Gonna be a big player in NASH related industry.
GL
BIVI moved from the OTC to the Nasdaq:
https://otce.finra.org/otce/dailyList?viewType=Deletions
I had 50k shares in Nanoantibiotics - anyone know how many shares that is now after the reverse split that they had?
Amended S1 is out today...finally a sign of life! Hopefully funding pulls through soon to get this boat moving again.
https://www.otcmarkets.com/stock/BIVI/disclosure
Honestly, I'm not an expert with evaluations and I wouldn't be able to estimate. Maybe someone else on the forum could give a possible SWAG?
I Hope you are right! How much do you think is the offer, considering no more Intellectual Property (revoked after losing Mallinkcrodt's patent challenge) on hand but 1 pending?
Director Hari Kumar resigned from the Company’s Board of Directors effective February 12, 2020. Dr. Kumar had served as a director since May 2017. The Company appreciates the dedicated service of Dr. Kumar.
https://www.sec.gov/Archives/edgar/data/1580149/000152013820000056/bivi-20191231_10q.htm
Nasdaq Listing WITHDRAWN! :(
February 13, 2020
Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, N.E
Washington, DC 20549
Re: Biovie Inc.
Amendment Withdrawal Request
Form 8-A/A Filed October 2, 2019
File No. 001-39015
Ladies and Gentlemen:
BioVie Inc. hereby requests the withdrawal of its Registration Statement on Form 8-A originally filed with the Commission on August 2, 2019 and as amended on October 2, 2019.
The Company confirms no securities will be listed on a national securities exchange in connection with the offering. In the event the Staff has any questions with respect to this matter, please call either Norwood Beveridge at (212) 407-4970 or Lili Taheri at (212) 407-4160.
Thank you very much for your time and attention in connection with this matter.
Sincerely,
/s/ Joanne Wendy Kim
Joanne Wendy Kim, Chief Financial Officer and Corporate Secretary
https://www.sec.gov/Archives/edgar/data/1580149/000152013820000057/bivi-rw.htm
$30k on the bid right now...is the bottom in??? news coming???
Waiting on financing news which is taking pretty long...
Extremely low float here at 332k!!!
Once this stock gains traction with financing/trials this will float on air going up...
New Delivery System Designed to Enable Home Care Therapy
"BioVie’s new patent-pending formulation of terlipressin has demonstrated the potential for room-temperature storage. If extended room-temperature product stability can be shown, this feature could provide another key product advantage. To the best of the Company’s knowledge, all other terlipressin products sold globally must be stored under refrigeration and there are no prefilled syringe formats available for treating patients."
"In addition, the Company has a pending patent application covering the proprietary liquid formulation of terlipressin to be used in its planned Phase 2b/3 trial, subject to FDA clearance. This could eventually provide up to 20 years of patent coverage in each country for which the Company seeks patent protection, including the US, according to the patent laws of that country."
NEWS out today!!!
https://irdirect.net/prviewer/release/id/4173086
Tailwinds’ Take: "this is exciting news for BioVie. If BIV201 gets approved, one can assume the drug will gain fairly quick and broad acceptance not only for efficacy but cost savings reasons. The next step for the Company remains financing for the trials, hopefully to close sometime in December."
Tailwinds Take!
BioVie (BIVI): the on-again, off-again, financing and uplisting seems to be moving into a two-part transaction. The reverse split happened on Friday, I believe. From what I hear, after it trades over the Nasdaq minimum for 10 days, they will do the financing and uplisting. Once that risk is off the table, this one has some upside on a drug that contains relatively little FDA approval risk.
https://tailwindsresearch.com/2019/11/deep-fried-turkey/
NASDAQ bound!
On November 20, 2019, the last reported sale price for our common stock as reported on the OTCQB Marketplace was $5.00 per share, after giving effect to our recently effected 1:125 reverse stock split. The final public offering price will be determined through negotiation between us and the lead underwriters in the offering and the recent market price used throughout this prospectus may not be indicative of the final offering price. Our common stock and warrants have been approved for listing on The NASDAQ Capital Market (“Nasdaq”) under the symbols “BIVI” and “BIVIW,” respectively.
https://www.sec.gov/Archives/edgar/data/1580149/000152013819000485/bivi-20191122_s1a8.htm
Thanks Trend and Ejob for keeping things updated while I was out.
Yes, now I see 6 shares but no price showing, just a bid of 4.10 and ask of 6.84 and the high and low of .053
E-Trade doesn't show a change on my portfolio yet.
One share has been traded thus far...lol
So..RS kicks in this time. Why no movement yet? Pending News?
Right, fewer shares now due to the 1:125 reverse split.
Your account has to settle the funds essentially during the splitting process. Its very common for this process to take place during a split but if you need a more formal answer, you can call your trading platform for more concrete answer to what your account is showing.
Ahh! So during a reverse split, the stock value goes to 0 and then is updated? Because now I see the real value again, but with fewer shares at higher value per share.
Cool. Makes sense.
I think I understand the concept - but why is the value of my investing account $0 now? It went from $5000 to $0. It's worrying, so I'd like a little bit more insight than a google search on reverse split. Thanks
What does this split mean for us investors who had purchased around 98.000 shares, worth roughly $5000 before the split? I'm a novice with investing so I'm still learning.
BIVI one for 125 reverse split effective tomorrow.
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
That's one thing to avoid now considering the patent challenge outcome. This completely nullified BIVI's IP and has significantly impacted its enterprise value. imo. RS is not a good thing at this time, imo. Shorts will be over this stock if it happens.
Completely surprised about the bad outcome of the IP challenge.
Reverse split announced!
Lets see if it follows through this time.
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
Sadly to say, MNK prevailed :(
Item 8.01 Other Events.
On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.
BioVie is evaluating the Board’s decision to determine if it will request a rehearing by the Board or appeal the Board’s decision to the U.S. Court of Appeals for the Federal Circuit. This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues on the pending application according to the patent laws of each issuing country.
https://www.sec.gov/Archives/edgar/data/1580149/000152013819000459/bivi-20191115_8k.htm
PART III - NARRATIVE
Additional time is needed to update status of a proceeding before the USPTO Patent Trial and Appeal Board.
https://ih.advfn.com/stock-market/USOTC/biovie-qb-BIVI/stock-news/81150672/notification-that-quarterly-report-will-be-submitt
Watch your words! No dummies here! But FWIW, First attempt YES, everyone here is aware! But second attempt? Are you referring to second attempt? If so, can you provide the link?
BIVI one for 125 reverse split:
https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
If the outcome in favor of BIVI coupled with the start of Nasdaq trading is publicly released, this gem will fly. IMO. In addition, a pending start of BIV201 Ph2b/3 clinical trial is imminent.
PATENT CHALLENGE MNK vs. BIVI
SEC S-1/A pg.6
On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.
On August 15, 2018, we submitted a Preliminary Response to the PTAB providing a rationale as to why, in our opinion, Mallinckrodt’s request to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood of success in proving that at least one of our 14 claims was unpatentable. On March 7, 2019, we submitted a Patent Owner’s Response and a Patent Owner’s Contingent Motion to Amend our patent claims, and Declaration of Dr. Jaime Bosch, MD, PhD, our medical expert. On June 26 and June 28, 2019, we submitted a Patent Owner’s Reply In Support Of Its Contingent Motion To Amend Under 37 C.F.R.§ 42.121 to amend our patent claims and a Patent Sur-Reply supported by the Supplemental Declaration of Dr. Jaime Bosch to the Reply and the Opposition to Motion to Amend, filed by Petitioner Mallinckrodt, filed June 6, 2019. On July 29, 2019, we submitted a Patent Owner’s Opposition to Petitioner’s Motion to Strike. On July 17, 2019, we received from the PTAB an Order Oral Hearing in response to our request of an Oral Hearing, which was held on August 12, 2019. We are actively defending the ’945 patent and we are exploring the possibility of settlement with Mallinckrodt. However, there can be no assurance that a favorable outcome will result, or if settlement is reached that the PTAB will accept it. Although the PTAB encourages settlement, in view of public-interest considerations, the PTAB may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due to settlement, the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019 (within one year from the date of institution).
We cannot guarantee investors that we will be successful in defending Mallinckrodt’s challenge against our patent. An unfavorable decision could reduce the scope of, or cancel, our patent rights, and allow third parties to commercialize our technology or products and compete directly with us, without payment to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to exploit our intellectual property or develop or commercialize current or future product candidates. Our ability to establish or maintain a technological or competitive advantage over our competitors and/or market entrants may be diminished because of these uncertainties. For these and other reasons, our intellectual property may not provide us with any competitive advantage.
In addition, you should note that as of June 30, 2019, no adjustments or accruals have been reflected in our financial statements related to this matter.
https://www.sec.gov/Archives/edgar/data/1580149/000152013819000418/bivi-20191101_s1a7.htm
WHO WILL PREVAIL ? Next week, Nov. 14, 2019 <<< FINAL DECISION
Nice to see another face on this board and to help with the DD! Good find!
Nasdaq bound! Not kicked in yet. Anytime today?
1:125 R/S Tomorrow, per FINRA: https://otce.finra.org/otce/dailyList
BIVID
SEC S-1/A Filed 11/01/2019 >>> BIVI Nasdaq bound very soon!
https://www.sec.gov/Archives/edgar/data/1580149/000152013819000418/bivi-20191101_s1a7.htm
UPDATED CORPORATE PRESENTATION Oct.2019
https://www.biovieinc.com/wp-content/uploads/2019/10/BioVie-Corp-Presentation_website_Oct-2019.pdf
Tailwinds’ Take: the endpoints for this trial, time to recurrence and volume removed, should be easy for a well-known drug like Terlipressin to achieve. Next step for BIVI is obtaining funding. Once funded, this could be one of the lowest risk clinical trials we’ve seen.
https://tailwindsresearch.com/2019/10/biovie-submits-protocol-for-phase-2b-3-refractory-ascites-study-to-fda/
Followers
|
43
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
878
|
Created
|
01/30/14
|
Type
|
Free
|
Moderators |
With no medications approved by the FDA specifically to treat ascites, the prognosis for these patients is very poor. Certain drugs which have been approved for other medical conditions (such as diuretics) combined with a salt restricted diet usually provide symptomatic relief in the initial stages of the disease. But as the ascites worsens their efficacy often diminishes. BioVie is working on a solution to address this critical unmet medical need.
Julie G. Anderson, Director. Anderson most recently served Catheter Connections, Inc. as its Vice President of Marketing until the company was sold last month. Previously she was Senior Director of Marketing for Durata Therapeutics, Inc., playing a key role in helping build the infrastructure and commercialization plan necessary to launch the novel antibiotic Dalvance. The team's efforts led to an acquisition of the company in 2014 by Actavis (now Allergan) in a deal valued at about $675 million. Prior to Durata, Julie worked for Sanofi-Synthelabo, Inc., Bayer Pharmaceuticals, and G.D. Searle in various marketing leadership positions. She originally trained as a nurse and earned a Masters of Management at the J.L. Kellogg Graduate School of Management at Northwestern University. As a critical care nurse, Julie treated patients at risk of death due to complications caused by chronic liver cirrhosis, and deeply understands the unmet medical need targeted by BioVie.
Hari Kumar, Director. Board of Directors as an independent director. In addition, Dr. Kumar purchased common shares of BioVie stock through a private placement. After earning a PhD in immunology in 1984, Dr. Kumar embarked upon a successful career in the biopharmaceutical industry. He held positions of increasing responsibility at Roche Pharma culminating in serving as Global Business Development Director, and in 2007 assumed the role of Chief Business Officer for Amira Pharmaceuticals. He led the sale of Amira to Bristol-Myers Squibb in 2011 for $475 million. He then served as Chief Executive Officer (CEO) for Panmira Pharmaceuticals LLC, which is developing anti-inflammatory compounds, and in 2013 became CEO for Adheron Therapeutics, which Roche Pharma acquired in 2015 for $580 million. Beyond his impressive track record, Dr. Kumar brings deep experience in fibrotic and liver diseases to the Company.
Press Releases: https://finance.yahoo.com/quote/bivi?p=bivi
In the News:
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |